Ernexa Therapeutics (ERNAW) Debt Ratio (2013 - 2026)

Ernexa Therapeutics' (ERNAW) quarterly Debt Ratio came in at 0.0 in Q1 2026, down 44.66% on a QoQ basis from 0.01 in Q4 2025.

Analysis

Ernexa Therapeutics (ERNAW) Debt Ratio (2013 - 2026) Analysis & Trends

Ernexa Therapeutics (ERNAW) has 13 years of Debt Ratio data on file, last reported at 0.0 in Q1 2026.

Quarterly Debt Ratio changed N/A year-over-year to 0.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.0 (changed N/A YoY) and the FY2025 annual result came in at 0.01, changed N/A from the prior year.
Debt Ratio eased to 0.0 in Q1 2026, from 0.01 in the prior quarter.
In the past five years, Debt Ratio ranged from a high of 0.17 in Q1 2023 to a low of 0.0 in Q1 2026.
A 4-year average of 0.05 and a median of 0.01 in 2025 frame the typical range for Debt Ratio.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	0.05
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	0.05
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	0.12
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	-
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	0.47
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	0.26
10	Ernexa Therapeutics	67,312.70	67,312.70	-	-

Historic Data

Download Data